SkQ1
Aliases: Plastokvinonil-dekiltrifenilfosfonijum · Visomitin
Last verified: 2026-09-23
The short version
A mitochondria-targeted antioxidant (Skulachev ion) — eye drops approved in Russia (Visomitin); studied for dry eye and cardioprotection. Key fact: No controlled human trials exist. Everything known about SkQ1 in humans comes from indirect sources and self-reports. Status: in clinical trials. Approved in Russia (drops); otherwise investigational.
Identity & type
- Molecular type
- mali molekul
- Origin
- A mitochondria-targeted antioxidant (Skulachev ion) — eye drops approved in Russia (Visomitin); studied for dry eye and cardioprotection.
Mechanism of action
Accumulates in mitochondria (TPP+ carrier) → neutralizes ROS at the source.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for SkQ1. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Eye drops 1–2× daily; oral experimental. Eye drops (Russia): reduced dryness and irritation; oral use is rare and investigational.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Eye drops (Russia): reduced dryness and irritation; oral use is rare and investigational.
Protocol — official vs community
Official / label
No official protocol exists — this compound has no approved product.
Community (anecdotal)
Visomitin eye drops, 1–2 drops 1–2× daily, as sold in Russia; oral systemic use appears only in self-experimentation circles with no standardized dose.
- Cycle:
- Continuous for the eye-drop use.
- Break:
- None reported.
Niche longevity and dry-eye use of a mitochondria-targeted antioxidant. Human data exist only for topical ocular use; human systemic pharmacokinetics, dosing and safety are simply absent from the literature.
Human evidence
No controlled human trials exist. Everything known about SkQ1 in humans comes from indirect sources and self-reports.
Preclinical evidence
Russian studies + US Phase II/III for dry eye (mixed outcomes).
Known risks
- Mild stinging (drops).characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- All human pharmacokinetics, safety and efficacy
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.